BOPI 05 BR / 2025 REPERTOIRE NUMERIQUE 17 Formula IV ________________________________________ (11) 21895 Consulter le mémoire (51) A61K 31/443 (2018.01); A61P 29/00 (2018.01); C07D 405/12 (2018.01) (21) 1202300469 - PCT/US2022/032116 (22) 03/06/2022 (30) US n° 63/196,946 du 04/06/2021 (54) N-(HydroxyalkyI (Hetero) Aryl) Tetrahydrofuran carboxamides as modulators of sodium channels. (72) Elizabeth Mary BECK (US); Robert PULLIN (US); Gorka ETXEBARRIA JARDI (US); Dean STAMOS (US); Yvonne SCHMIDT (US); Joseph PONTILLO (US); Stephen Andrew THOMSON (US); David Matthew SHAW (US); Nadia AHMAD (US); Lidio Marx CARVALHO MEIRELES (US); Sarah SKERRATT (US); Sara S. HADIDA RUAH (US); Timothy Donald NEUBERT (US); Dennis James HURLEY (US); Jinglan ZHOU (US); Steven John DURRANT (US); Christopher WRAY (US); Anisa NIZARALI VIRANI (US); Kiri NORTH (US); James DODD (US); Michael Edward O'DONNELL (US); Bhairavi GALAN (US); Ronald Marcellus KNEGTEL (US); Ewa IWONA CHUDYK (US) et Joanne Louise PINDER (US) (73) VERTEX PHARMACEUTICALS INCORPORATED, 50 Northern Avenue, BOSTON, Massachusetts 02210 (US) (74) Cabinet SPOOR & FISHER Inc. NGWAFOR & PARTNERS SARL, The House of Gideon, Golf/Bastos Quater, Opposite The American Embassy, Entrance-Saint John Paul II Boulevard, P.O. Box 8211, YAOUNDE (CM). (57) Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain. Formula I
RkJQdWJsaXNoZXIy MTM1NDc3MA==